ArticleAntimicrobial agents and chemotherapy1998
Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.Antimicrobial agents and chemotherapy · 2022Pooled it
- Doripenem Treatment during Continuous Renal Replacement Therapy.Antimicrobial agents and chemotherapy · 2015Trial
- A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Critical care (London, England) · 2015Trial
- Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.Intensive care medicine · 2008Trial
- Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Antimicrobial agents and chemotherapy · 2005Trial
- Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients.CPT: pharmacometrics & systems pharmacology · 2026Article
- Development and validation of a machine learning model for individualised meropenem dosing in CRRT patients.Scientific reports · 2026Article
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Analytical and Clinical Validation of Assays for Volumetric Absorptive Microsampling (VAMS) of Drugs in Different Blood Matrices: A Literature Review.Molecules (Basel, Switzerland) · 2023Review
- Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistantScience advances · 2019Article
- A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.Clinical pharmacokinetics · 2019Article
- Beta-lactam carryover in arterial and central venous catheters is negligible.Clinica chimica acta; international journal of clinical chemistry · 2018Article
- Article
- Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Antimicrobial agents and chemotherapy · 2015Article
- Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.Critical care (London, England) · 2014Review
- [Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2014Review
- Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.Antimicrobial agents and chemotherapy · 2014Article
- Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Annals of intensive care · 2012Article
- Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.Critical care (London, England) · 2011Article
- Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.Antimicrobial agents and chemotherapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH). All patients received one dose of 1 g of meropenem intravenously. High-flux polysulfone membranes were used as dialyzers. Meropenem levels were measured in plasma and ultrafiltrate by high-performance liquid chromatography. The total body clearance and elimination half-life were 143.7 +/- 18.6 ml/min and 2.46 +/- 0.41 h, respectively. The post- to prehemofiltration ratio of meropenem was 0.24 +/- 0.06. Peak plasma drug concentrations measured 60 min postinfusion were 28.1 +/- 2.7 microgram/ml, and trough levels after 6 h of CVVH were 6.6 +/- 1.5 microgram/ml. The calculated total daily meropenem requirement in these patients with acute renal failure and undergoing CVVH was 2,482 +/- 321 mg. Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.